MX2022012092A - Moleculas de union al antigeno multiespecificas dirigidas a claudina-6 y sus usos. - Google Patents

Moleculas de union al antigeno multiespecificas dirigidas a claudina-6 y sus usos.

Info

Publication number
MX2022012092A
MX2022012092A MX2022012092A MX2022012092A MX2022012092A MX 2022012092 A MX2022012092 A MX 2022012092A MX 2022012092 A MX2022012092 A MX 2022012092A MX 2022012092 A MX2022012092 A MX 2022012092A MX 2022012092 A MX2022012092 A MX 2022012092A
Authority
MX
Mexico
Prior art keywords
cldn6
binding
binding molecules
multispecific antigen
claudin
Prior art date
Application number
MX2022012092A
Other languages
English (en)
Inventor
Shinya Ishii
Tatsushi KODAMA
Naoki Kimura
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2022012092A publication Critical patent/MX2022012092A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain

Abstract

La presente invención se refiere a moléculas multiespecíficas de unión al antígeno capaces de unirse a CD3 y CD137 (4-1BB) pero no de unirse a CD3 y CD137 al mismo tiempo, y capaces de unirse a CLDN6. Las moléculas de unión al antígeno multiespecíficas de la presente descripción exhiben una actividad de citotoxicidad dependiente de células T mejorada de una manera dependiente de CLDN6 mediante la unión a CD3/CD37 y CLDN6. La presente invención proporciona las moléculas de unión al antígeno multiespecíficas y las composiciones farmacéuticas de las mismas se pueden usar para dirigirse a células que expresan CLDN6, para usarse en inmunoterapia para tratar varios cánceres, especialmente aquellos asociados con CLDN6 tales como cánceres positivos para CLDN6.
MX2022012092A 2020-03-31 2021-03-30 Moleculas de union al antigeno multiespecificas dirigidas a claudina-6 y sus usos. MX2022012092A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020062881 2020-03-31
JP2020073335 2020-04-16
PCT/JP2021/013526 WO2021200939A1 (en) 2020-03-31 2021-03-30 Claudin-6 targeting multispecific antigen-binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
MX2022012092A true MX2022012092A (es) 2022-10-13

Family

ID=77928433

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012092A MX2022012092A (es) 2020-03-31 2021-03-30 Moleculas de union al antigeno multiespecificas dirigidas a claudina-6 y sus usos.

Country Status (17)

Country Link
US (1) US20230220066A1 (es)
EP (1) EP4126956A4 (es)
JP (2) JP6971419B2 (es)
KR (2) KR102431028B1 (es)
CN (1) CN115397855A (es)
AU (1) AU2021247916A1 (es)
BR (1) BR112022017305A2 (es)
CA (1) CA3174094A1 (es)
CL (2) CL2022002625A1 (es)
CO (1) CO2022015202A2 (es)
CR (1) CR20220540A (es)
IL (1) IL296478A (es)
MX (1) MX2022012092A (es)
PE (1) PE20221760A1 (es)
SG (1) SG11202104264TA (es)
TW (2) TWI770917B (es)
WO (1) WO2021200939A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160280787A1 (en) 2013-11-11 2016-09-29 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified antibody variable region
US11952422B2 (en) 2017-12-05 2024-04-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137
JPWO2023053282A1 (es) * 2021-09-29 2023-04-06
WO2023131329A1 (en) * 2022-01-09 2023-07-13 I-Mab Biopharma Co., Ltd. Multispecific constructs and uses thereof
WO2024085166A1 (ja) * 2022-10-19 2024-04-25 アステラス製薬株式会社 がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9274119B2 (en) 2008-01-11 2016-03-01 The University Of Tokyo Anti-CLDN6 antibody
KR102126964B1 (ko) 2009-11-11 2020-06-25 가니메드 파마슈티칼스 게엠베하 클라우딘 6 특이적 항체
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
AU2012258087B2 (en) 2011-05-13 2017-07-20 Astellas Pharma Inc. Antibodies for treatment of cancer expressing claudin 6
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
MX369276B (es) 2012-11-13 2019-11-04 Biontech Ag Agentes para tratamiento de enfermedades cancerosas que expresan claudina.
SG11201603397QA (en) 2013-11-06 2016-05-30 Stemcentrx Inc Novel anti-claudin antibodies and methods of use
WO2018054484A1 (en) * 2016-09-23 2018-03-29 Biontech Ag Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
US11952422B2 (en) * 2017-12-05 2024-04-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137
US20210054076A1 (en) * 2018-01-05 2021-02-25 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
CN113260634A (zh) * 2018-09-28 2021-08-13 中外制药株式会社 包含改变的抗体可变区的抗原结合分子
MX2022000111A (es) * 2019-07-10 2022-02-10 Chugai Pharmaceutical Co Ltd Moleculas de union a claudina-6 y usos de las mismas.

Also Published As

Publication number Publication date
PE20221760A1 (es) 2022-11-11
US20230220066A1 (en) 2023-07-13
EP4126956A4 (en) 2024-04-24
BR112022017305A2 (pt) 2022-10-11
JP2021168648A (ja) 2021-10-28
CR20220540A (es) 2022-12-07
TWI770917B (zh) 2022-07-11
AU2021247916A1 (en) 2022-10-20
IL296478A (en) 2022-11-01
TW202204408A (zh) 2022-02-01
CL2023002099A1 (es) 2023-12-22
KR20210143923A (ko) 2021-11-29
JP6971419B2 (ja) 2021-11-24
CO2022015202A2 (es) 2022-11-18
EP4126956A1 (en) 2023-02-08
WO2021200939A1 (en) 2021-10-07
CL2022002625A1 (es) 2023-04-21
CN115397855A (zh) 2022-11-25
KR102431028B1 (ko) 2022-08-10
KR20220149774A (ko) 2022-11-08
SG11202104264TA (en) 2021-11-29
TW202235442A (zh) 2022-09-16
JP2022009816A (ja) 2022-01-14
CA3174094A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
CR20220540A (es) Moléculas de union al antígeno multiespecíficas dirigidas a claudina-6 y sus usos
PH12019501056A1 (en) Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
PH12017500507A1 (en) Cytotoxicity-inducing therapeutic agent
WO2018234793A3 (en) Antibodies
MX2019006954A (es) Terapia de combinacion de anticuerpos biespecificos anti-cd20/anti-cd3 y agonistas de 4-1bb (cd137).
MX2020012130A (es) Proteinas multiespecificas de union de direccionamiento a anhidrasa carbonica 9 (caix), anoctamina-1 (ano1), mesotelina, antigeno de superficie celular de trofoblasto (trop2), antigeno carcinoembrionario (cea) o claudina-18.2.
MX2018001954A (es) Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos.
NZ739830A (en) Bridge linkers for conjugation of cell-binding molecules
EP4273258A3 (en) Proteins binding her2, nkg2d and cd16
MX2019009566A (es) Proteinas de union a bcma, nkg2d y cd16.
PH12020551689A1 (en) Her2-targeting antigen binding molecules comprising 4-1bbl
CR20210622A (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
MX2020006116A (es) Terapia combinada de agonistas de icos dirigidos a tumores con moleculas biespecificas de linfocitos t.
MY192295A (en) Peptides and methods for the treatment of diabetes
MX2022005330A (es) Moleculas de union multiespecificas con scfv en el extremo nterminal.
WO2018170150A3 (en) Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins
CR20220656A (es) Unión de anticuerpos multiespecíficos a bcma
MX2019009943A (es) Proteínas que se unen a gd2, nkg2d y cd16.
WO2006102209A3 (en) Cd34(+) cells and their methods of use
MX2019009847A (es) Proteínas que se unen a cd123, nkg2d y cd16.
SG11201910113PA (en) Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate
PH12019550194A1 (en) Anti-ceacam1 antibody and use thereof
WO2019075216A8 (en) Plectin-1 binding antibodies and uses thereof
WO2019078697A3 (ko) 항" cd3항체 및 이를포함하는 암치료용 약학적 조성물
MX2022013237A (es) Maltodextrinas entrelazadas para el suministro oral de activos biologicos.